See the latest vacancies and find out about working for MSF IrelandJobs in Ireland
Uzbekistan was once at the heart of the ancient Silk Road trade route connecting China with the Middle East and Rome.
In 1991, Central Asia’s most populous country emerged from more than 200 years of Russian rule as an independent state.
From 1989 to September 2016, the country had been ruled by President Islam Karmov.
Médecins Sans Frontières/Doctors Without Borders (MSF) has worked in Uzbekistan since 1997 and continues to work to improve the quality and availability of treatment for Tuberculosis (TB), which has high levels of the drug-resistant form of the disease.
In Uzbekistan, Médecins Sans Frontières works to improve the quality and availability of treatment for tuberculosis (TB) and HIV.
Our TB project in Nukus, the capital of the Autonomous Republic of Karakalpakstan, has two components: comprehensive patientcentred care and clinical research into shorter, more tolerable and more effective treatments. Our approach includes a shorter, nine-month treatment regimen and homebased outpatient care.
In 2018, we started 2,220 patients on TB treatment. Of these, 660 were drugresistant in some form, including 450 multidrug-resistant and 70 extensively drug-resistant cases; 199 were treated with new or repurposed drugs. We are supporting the rollout of World Health Organization treatment recommendations throughout Karakalpakstan, where we also manage a state-of-the-art laboratory equipped with some of the most advanced diagnostic instruments.
We launched the multi-site TB PRACTECAL clinical trial in Nukus in 2017 to evaluate the effectiveness of two of the newest TB drugs – bedaquiline and pretomanid – on a much shorter regimen of just six months. By the end of 2018, the Nukus site had recruited 104 patients and an additional site in Tashkent had been approved to start recruitment in early 2019.
We also work with the Ministry of Health to care for people living with HIV. Based in Tashkent since 2013, our project focuses on integrated care for HIV patients coinfected with either hepatitis C, syphilis, or other sexually transmitted infections. In 2018, we began working in clinics that serve at-risk groups such as sex workers, people who inject drugs and men who have sex with men. In 2018, we initiated 750 people on hepatitis C treatment and 810 on antiretroviral (ARV) therapy for HIV.